Important roles of C5a and C5aR in tumor development and cancer treatment

Wang, Yuxuan

doi:10.1051/e3sconf/201913606012

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In animal models of lung cancer, gastric cancer and ovarian cancer, downregulation, silencing or inhibition of C5aR1 can reduce tumor proliferation, angiogenesis, tumor growth and metastasis [ 23 ]. Therefore, C5aR1 may be a new biological indicator and therapeutic target for many solid tumors [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/β-catenin pathway

Ran

et al. 2022

Clin Transl Oncol

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is one of the most common malignant cancers in human, and its incidence increases gradually every year. Metastasis is an important factor leading to tumor development. The epithelial–mesenchymal transition (EMT) has been proved to be closely related to tumor metastasis, yet its related mechanism in CRC remains to be explored. Methods We obtained the differentially expressed gene C5aR1 with SETDB1 stable overexpression and knockdown cells by RNA-seq. Cell proliferation was tested by CCK8 and colony formation assay. Migration and invasion of CRC cells were determined by the wound healing and transwell invasion assay. The potential pathway of C5aR1 in CRC was preliminarily studied by western blotting. Results Sequencing results showed that C5aR1 was the most differentially expressed gene. By changing the expression of C5aR1 in CRC cells, this study found that C5aR1 promoted the proliferation, colony formation, migration and invasion of CRC cells in vitro. C5aR1 accelerated the EMT process and the expression of C5aR1 altered the molecular expression of key proteins in the Wnt/β-catenin pathway. Conclusion C5aR1 promotes the development of CRC and accelerates the EMT process. Furthermore, C5aR1 may involve in the regulation of Wnt/β-catenin pathway in CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/β-catenin pathway

Ran

et al. 2022

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…Patients with positive or high expression in lung, breast, kidney and gastric cancer showed lower survival rate than that of patients with negative expression (Yuxuan, 2019). An abnormal expression of this receptor has been associated with activation of downstream pathways with beneficial processes that promotes tumor progression and metastasis (Yuxuan, 2019). In relation to breast cancer, the correlation between C5AR1 expression in cancer cells and the tumor development suggests this receptor might be closely associated with breast cancer progression and even could be considered as a new target, in particular to triple-negative breast cancer (TNBC), despite not being considered a specific biomarker (Imamura et al, 2016).…”

Section: C5ar1 and Cx3cr1 Are Potential Targets Of Peptmentioning

confidence: 93%

“…C5AR1 has been found in tumor cells of several cancers. Patients with positive or high expression in lung, breast, kidney and gastric cancer showed lower survival rate than that of patients with negative expression (Yuxuan, 2019). An abnormal expression of this receptor has been associated with activation of downstream pathways with beneficial processes that promotes tumor progression and metastasis (Yuxuan, 2019).…”

Section: C5ar1 and Cx3cr1 Are Potential Targets Of Peptmentioning

confidence: 99%

Selection of a new peptide homing SK‐BR‐3 breast cancer cells

et al. 2020

View full text Add to dashboard Cite

Breast cancer diagnosis remains a challenge, mostly due to its heterogeneity. This reality translates in delayed treatments, increasing treatment aggressiveness and lower chances of overall survival. The conventional detection techniques, although becoming increasingly sophisticated each year, still lack the ability to provide reliable conclusions without being time consuming, expensive, and uncomfortable for the patients. The identification of novel biomarkers for breast cancer research is therefore of utmost relevance for an early diagnosis. Moreover, breast cancer-specific peptide moieties can be used to develop novel targeted drug delivery systems. In this work, we used phage display to identify a novel peptide with specificity to the SK-BR-3 breast cancer cell line. Cytometry assays confirmed its specificity, while bioinformatics and docking studies predicted the potential biomarkers at the SK-BR-3 cells' surface. These findings can be potentially useful in the clinical context, contributing to more specific and targeted therapeutic solutions against HER2-positive breast cancer subtypes.

show abstract

Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues

et al. 2021

View full text Add to dashboard Cite

The complement component C5a and its receptor C5aR1 are involved in the development of numerous inflammatory diseases. In addition to immune cells, C5aR1 is expressed in neoplastic cells of multiple tumour entities, where C5aR1 is associated with a higher proliferation rate, advanced tumour stage, and poor patient outcomes. The aim of the present study was to obtain a broad expression profile of C5aR1 in human non-neoplastic and neoplastic tissues, especially in tumour entities not investigated in this respect so far. For this purpose, we generated a novel polyclonal rabbit antibody, {5227}, against the carboxy-terminal tail of C5aR1. The antibody was initially characterised in Western blot analyses and immunocytochemistry using transfected human embryonic kidney (HEK) 293 cells. It was then applied to a large series of formalin-fixed, paraffin-embedded non-neoplastic and neoplastic human tissue samples. C5aR1 was strongly expressed by different types of immune cells in the majority of tissue samples investigated. C5aR1 was also present in alveolar macrophages, bronchial, gut, and bile duct epithelia, Kupffer cells, occasionally in hepatocytes, proximal renal tubule cells, placental syncytiotrophoblasts, and distinct stem cell populations of bone marrow. C5aR1 was also highly expressed in the vast majority of the 32 tumour entities investigated, where a hitherto unappreciated high prevalence of the receptor was detected in thyroid carcinomas, small-cell lung cancer, gastrointestinal stromal tumours, and endometrial carcinomas. In addition to confirming published findings, we found noticeable C5aR1 expression in many tumour entities for the first time. Here, it may serve as an interesting target for future therapies.

show abstract

Important roles of C5a and C5aR in tumor development and cancer treatment

Cited by 3 publications

References 19 publications

C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/β-catenin pathway

C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/β-catenin pathway

Selection of a new peptide homing SK‐BR‐3 breast cancer cells

Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues

Contact Info

Product

Resources

About